Identification of Fangjihuangqi Decoction as a late-stage autophagy inhibitor with an adjuvant anti-tumor effect against non-small cell lung cancer

Qiugu Chen, Yuan Liao, Yujiao Liu, Yue Song, Junbo Jiang, Zhen Zhang, Anqi Li, Mengyi Zheng, Xiaoyi Chen, Tingxiu Zhao, Jiangyong Gu, Yuhui Tan, Xiaoyi Liu, Yanjun Jiang, Kun Wang, Yi Hua, Jianyong Xiao, Shan HuChinese 2023 · DOI

This study, published in Chinese Medicine, identifies Fangjihuangqi Decoction (FJHQ)—a traditional herbal formula—as a potent late-stage autophagy inhibitor. By preventing the maturation of lysosomal enzymes, FJHQ causes a "traffic jam" in the cell’s waste-disposal system, leading to a buildup of reactive oxygen species (ROS) that synergistically enhances the killing power of standard chemotherapies against non-small cell lung cancer (NSCLC).

TL;DR

Researchers have discovered that the traditional Chinese medicine FJHQ acts as a "sensitizer" for lung cancer treatment by blocking the late stages of autophagy. This inhibition prevents cancer cells from cleaning up damaged mitochondria, leading to a toxic buildup of ROS that triggers apoptosis and overcomes chemoresistance.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While chemotherapy drugs like cisplatin and paclitaxel are first-line treatments, they often trigger a survival mechanism in cancer cells called autophagy.

Think of autophagy as a cellular recycling program: when stressed by chemo, cancer cells use it to eat their own damaged parts to stay alive, leading to drug resistance. While drugs like hydroxychloroquine (HCQ) can block this process, they often carry significant side effects. There is a pressing need for safer, more effective adjuvant therapies that can inhibit this "pro-survival" autophagy and make tumors more vulnerable to treatment.

Methods

The researchers employed a multi-disciplinary approach to dissect FJHQ’s mechanism:

  • Standardization: Used UPLC/Q-TOF-MS/MS to identify the chemical fingerprint of the six-herb FJHQ decoction.
  • Autophagic Flux Analysis: Utilized tandem mCherry-GFP-LC3B reporters and confocal microscopy to determine exactly where the autophagic process was being interrupted.
  • Biochemical Assays: Measured protein levels of LC3-II and P62 (autophagy markers) and the maturation of cathepsins B, D, and L (lysosomal enzymes).
  • Synergy Modeling: Calculated "Q-values" to determine if the combination of FJHQ and chemotherapy was truly synergistic (Q > 1.15) or merely additive.
  • In Vivo Validation: Tested the FJHQ + cisplatin combination in NCI-H1299 xenograft mouse models to observe tumor growth inhibition in a living system.

Datasets

As a biological mechanistic study, the "datasets" consist of specific cell lines and animal models:

  • Cell Lines: NCI-H1299 (p53-deficient), A549, and NCI-H1975 (EGFR-mutant) human lung cancer cells.
  • Animal Models: Male BALB/C nude mice used for human lung cancer xenografting.
  • Chemical Profiling: A library of 15 representative compounds identified within FJHQ (e.g., Tetrandrine, Glycyrrhizic acid).

Key Insights and Ideas

  • The "Traffic Jam" Mechanism: Most autophagy inhibitors either stop the process at the start or prevent the autophagosome from fusing with the lysosome. FJHQ is unique; it allows fusion to occur but prevents the maturation of cathepsins (the acidic "scissors" inside the lysosome). The cell ends up full of "clogged" autolysosomes that cannot digest their cargo.
  • Mitochondrial Sabotage: By blocking autophagy, FJHQ prevents the clearance of mitochondria damaged by chemotherapy. These "leaky" mitochondria spill Reactive Oxygen Species (ROS) into the cell.
  • The ROS-MAPK Suicide Switch: The researchers proved that the resulting ROS accumulation activates the JNK and P38 MAPK pathways. This effectively flips a molecular switch that forces the cancer cell into programmed cell death (apoptosis).
  • Synergy, Not Just Addition: FJHQ alone had little effect on tumor growth, but when paired with cisplatin, it significantly amplified the drug's efficacy, suggesting its primary value is as an adjuvant (assistant) therapy.

Key Results

  • Inhibition of Flux: FJHQ significantly increased LC3-II and P62 levels in a dose-dependent manner, confirming a block in autophagic degradation.
  • Synergistic Killing: The combination of FJHQ with cisplatin or paclitaxel yielded Q-values > 1.15, indicating a strong synergistic effect on cell death.
  • In Vivo Efficacy: In mouse models, the FJHQ + cisplatin group showed significantly smaller tumor volumes and weights compared to the cisplatin-only group (P < 0.05).
  • Reversibility: The synergistic effect was almost entirely reversed when researchers added NAC (a ROS scavenger), proving that ROS accumulation is the primary driver of FJHQ’s anti-tumor activity.

Limitations and Future Work

  • Component Complexity: FJHQ is a "decoction" containing dozens of compounds. While the study identified 15 main ingredients, it remains unclear which specific molecule (or combination thereof) is responsible for the cathepsin inhibition.
  • Lysosomal pH: The authors noted that while FJHQ affects enzyme maturation, they have not yet fully explored whether it alters the internal pH of the lysosome, a common mechanism for other inhibitors like chloroquine.
  • Clinical Translation: While the mouse data is promising, human clinical trials are necessary to determine the optimal dosage and safety profile for cancer patients undergoing active chemotherapy.

Summary updated

Abstract

Collectively, these results demonstrate that FJHQ is a novel late-stage autophagy inhibitor that can amplify the anti-tumor effect of cisplatin and paclitaxel against NSCLC cells.
BibTeX
@inproceedings{chen2023identification,
  author = {Qiugu Chen and Yuan Liao and Yujiao Liu and Yue Song and Junbo Jiang and Zhen Zhang and Anqi Li and Mengyi Zheng and Xiaoyi Chen and Tingxiu Zhao and Jiangyong Gu and Yuhui Tan and Xiaoyi Liu and Yanjun Jiang and Kun Wang and Yi Hua and Jianyong Xiao and Shan Hu},
  title = {{Identification of Fangjihuangqi Decoction as a late-stage autophagy inhibitor with an adjuvant anti-tumor effect against non-small cell lung cancer}},
  booktitle = {Chinese},
  year = {2023},
  doi = {10.1186/s13020-023-00770-4},
}
Figure